1506 - AML FLT3 Maintenance Therapy

Go Back to BMT CTN Protocol Listing

  • Protocol Short Name and Number: AML FLT3 Maintenance Therapy, 1506
  • Protocol Long Name: A multi-center, randomized, double-blind, placebo-controlled Phase III trial of the FLT3 inhibitor gilteritinib administered as maintenance therapy following allogeneic transplant for patients with FLT3/ITD AML
  • Protocol (PDF)
  • Key Personnel
    • BMT CTN # 1506 Co-Chair: Mark Levis, MD
    • BMT CTN # 1506 Co-Chair: Yi-Bin Chen, MD
    • BMT CTN # 1506 Protocol Officer: Mehdi Hamadani, MD
    • BMT CTN # 1506 Protocol Coordinator: 1506DCC@emmes.com
  • Keywords: AML, Acute Myelogenous Leukemia, FLT3, Maintenance Therapy, Maintenance, FLT3 inhibitor gilteritinib